EMAIL DIGESTS
Daily
Every morning
Weekly
Sunday recap
T-CURX is a Biotech company developing personalized immunotherapies on the basis of CAR-T cells, leveraging cutting-edge technologies for targeted and chemotherapy-free cancer treatment.
No recent news for this company.
T-Curx Secures $20M Series A First Closing Led by BiomedVC